Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
26/08/2026 12:17
BUZZ-Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million ** Shares of drugmaker Biohaven BHVN.N rise 14% to $16.4 premarket
** Biohaven enters a partnership with South Korean drug maker SK Biopharmaceuticals 326030.KS worth up to $795 million to license and commercialize a new epilepsy drug platform
** SK Biopharmaceuticals gains exclusive global rights to Biohaven's lead epilepsy drug candidate, opakalim
** Opakalim is in mid-to-late stage trial testing for focal epilepsy, and trial results are expected in H2 2026
** Biohaven to use SK's established epilepsy development and sales network to bring opakalim to patients globally
** As of last close, BHVN up 27.4% YTD
(Reporting by Kamal Choudhury in Bengaluru)
Recent news on SK Biopharmaceuticals
See all newsBrief: Sk Biopharmaceuticals Co Signs Licensing-In Contract With 1St Biotherapeutics
US FDA pauses new enrollment in Biohaven's epilepsy drug trials (updated)
US FDA pauses new enrollment in Biohaven's epilepsy drug trials
Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
U.S. STOCKS ON THE MOVE-Meta, Kohl's, J.M. Smucker